Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | CHIEF FINANCIAL OFFICER | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 48,673 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Exercise / conversion · Acquired 7,197 · Balance 48,673 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Class A Common StockSEC Table I · non-derivative | Direct | 48,087 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 586 · Balance 48,087 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.23 to $94.855 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4. |
| Class A Common StockSEC Table I · non-derivative | Direct | 48,035 |
Reported balance
After 2026-09-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-16 · Sale · Disposed 52 · Balance 48,035 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $95.52 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 47,494 |
Reported balance
After 2026-09-16 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-16 · Sale · Disposed 541 · Balance 47,494 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.445 to $97.40 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 46,024 |
Reported balance
After 2026-09-16 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-16 · Sale · Disposed 1,470 · Balance 46,024 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.565 to $98.535 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 44,945 |
Reported balance
After 2026-09-16 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-16 · Sale · Disposed 1,079 · Balance 44,945 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $99.305 per share, inclusive. F8: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 44,945 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 71,667 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 14,393 |
Reported balance
After 2026-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-16 · Exercise / conversion · Disposed 7,197 · Balance 14,393 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F9: 6.25% of the total award vested or vests quarterly, with the first tranche vested on June 16, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.23 to $94.855 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $95.52 per share, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.445 to $97.40 per share, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.565 to $98.535 per share, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $99.305 per share, inclusive.
F8: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 44,945 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 71,667 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
F9: 6.25% of the total award vested or vests quarterly, with the first tranche vested on June 16, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 21:38 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 287 | $77.52 | $22,247.87 |
DisclosureSEC source: 0001944119-26-000008 · form4-03032026_090338.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,599 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.99 to $77.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 9,599 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 112,032 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:38 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-26-000008 · form4-03032026_090338.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,434 Underlying: Class A Common Stock · 718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on December 1, 2022. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F5 · derivative.expiration_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on December 1, 2022. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:38 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-26-000008 · form4-03032026_090338.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:33 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 754 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-26-000006 · form4-02022026_090237.xml · derivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754 Underlying: Class A Common Stock · 754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 25% of the total award vested on each of April 29, 2023 and April 29, 2024, and an additional 6.25% of the total award vested or vests thereafter on each quarterly anniversary, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the last tranche scheduled to vest on April 29, 2026. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F4 · derivative.expiration_date: 25% of the total award vested on each of April 29, 2023 and April 29, 2024, and an additional 6.25% of the total award vested or vests thereafter on each quarterly anniversary, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the last tranche scheduled to vest on April 29, 2026. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:33 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2 | $92.06 | $184.12 |
DisclosureSEC source: 0001944119-26-000006 · form4-02022026_090237.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,168 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 9,168 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 112,750 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:33 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 315 | $94.00 | $29,610.00 |
DisclosureSEC source: 0001944119-26-000006 · form4-02022026_090237.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,170 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:33 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 754 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-26-000006 · form4-02022026_090237.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · derivative · entry 13 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,984 Underlying: Class A Common Stock · 7,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F13 · derivative.exercise_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 16, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F13 · derivative.expiration_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 16, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 127 | $140.45 | $17,837.15 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 12 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,731 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F12 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 8,731 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 113,504 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 26 | $150.75 | $3,919.50 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 11 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,858 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 97 | $149.20 | $14,472.21 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 10 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,884 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.01 to $149.32, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 331 | $148.55 | $49,169.92 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 9 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,981 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.85 to $148.76, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 699 | $146.93 | $102,702.81 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 8 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,312 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.605 to $147.51, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 578 | $145.36 | $84,015.88 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 7 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,011 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.80 to $145.55, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 334 | $144.27 | $48,187.45 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 6 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,589 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.75 to $144.74, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 215 | $142.12 | $30,555.52 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 5 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,923 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.76 to $142.41, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 951 | $141.20 | $134,285.67 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,138 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.72 to $141.68, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 366 | $140.08 | $51,270.16 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,089 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.70 to $140.465, inclusive. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 131 | $138.93 | $18,199.83 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,455 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.65 to $139.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 11. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000021 · form4-12182025_101232.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000020 · form4-12112025_091200.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,849 Underlying: Class A Common Stock · 2,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 9, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F4 · derivative.expiration_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 9, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,266 | $159.28 | $201,648.48 |
DisclosureSEC source: 0001944119-25-000020 · form4-12112025_091200.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,389 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 5,389 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 120,701 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000020 · form4-12112025_091200.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000018 · form4-12032025_091247.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,152 Underlying: Class A Common Stock · 717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on December 1, 2022. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F6 · derivative.expiration_date: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on December 1, 2022. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 377 | $162.54 | $61,276.07 |
DisclosureSEC source: 0001944119-25-000018 · form4-12032025_091247.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,193 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.3501 to $162.5400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 4,193 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 123,163 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000018 · form4-12032025_091247.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · balance_after: The reported total includes 96 shares of the Issuer's Class A Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000015 · form4-10312025_081022.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,508 Underlying: Class A Common Stock · 753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 25% of the total award vested on each of April 29, 2023 and April 29, 2024, and an additional 6.25% of the total award vested or vests thereafter on each quarterly anniversary, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the last tranche scheduled to vest on April 29, 2026. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F4 · derivative.expiration_date: 25% of the total award vested on each of April 29, 2023 and April 29, 2024, and an additional 6.25% of the total award vested or vests thereafter on each quarterly anniversary, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the last tranche scheduled to vest on April 29, 2026. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 388 | $136.54 | $52,977.52 |
DisclosureSEC source: 0001944119-25-000015 · form4-10312025_081022.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,757 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · balance_after: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 3,757 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 123,880 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000015 · form4-10312025_081022.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $32.67 | $0.00 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · derivative · entry 9 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,982 Underlying: Class A Common Stock · 1,246 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F9 · derivative.exercise_date: The award vested or vests as to 6.25% of the total award quarterly over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 70 | $113.68 | $7,957.60 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 8 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,392 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F8 · balance_after: Following the reported sales effectuated pursuant to a 10b5-1 plan, in addition to the 3,392 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 124,633 shares of Class A common stock and options to purchase up to an aggregate of 25,906 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 520 | $111.93 | $58,204.22 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 7 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,462 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.50 to $112.04, inclusive. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 421 | $110.05 | $46,329.96 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 6 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,982 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.3225 to $110.25, inclusive. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,152 | $108.67 | $233,851.38 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 5 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,403 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.23 to $109.1754, inclusive. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,715 | $107.68 | $292,360.70 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,555 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.22 to $108.20, inclusive. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 387 | $106.86 | $41,353.81 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,270 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.1354 to $107.01, inclusive. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 344 | $105.24 | $36,202.97 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,657 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.98 to $105.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 7. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,246 | $32.67 | $40,706.82 |
DisclosureSEC source: 0001944119-25-000012 · form4-10012025_081020.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 01:50 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000005 · form4a-09192025_010943.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 22:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000003 · form4-09182025_100926.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,181 Underlying: Class A Common Stock · 7,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 22:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 3,728 | $121.47 | $452,850.23 |
DisclosureSEC source: 0001944119-25-000003 · form4-09182025_100926.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,755 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $118.28 to $123.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 with regard to the block trade. F4 · balance_after: Following the reported sales, in addition to the 8,755 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 124,633 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 22:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001944119-25-000003 · form4-09182025_100926.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024270 · form4-09112025_080926.xml · derivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,311 Underlying: Class A Common Stock · 2,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 6 | $129.09 | $774.54 |
DisclosureSEC source: 0001415889-25-024270 · form4-09112025_080926.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,286 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · balance_after: Following the reported sales, in addition to the 5,286 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 131,830 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,266 | $128.05 | $162,111.30 |
DisclosureSEC source: 0001415889-25-024270 · form4-09112025_080926.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,292 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024270 · form4-09112025_080926.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 22:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 378 | $125.81 | $47,556.03 |
DisclosureSEC source: 0001415889-25-023601 · form4-09032025_100956.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,096 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.2050 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · balance_after: Following the reported sales, in addition to the 4,096 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 134,292 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023601 · form4-09032025_100956.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,869 Underlying: Class A Common Stock · 717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023601 · form4-09032025_100956.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020715 · form4-07312025_080706.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,261 Underlying: Class A Common Stock · 753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 25% of the total RSUs vest on April 29, 2023 and April 29, 2024, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested on April 29, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 25% of the total RSUs vest on April 29, 2023 and April 29, 2024, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested on April 29, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.